Fundraising Fox
Reverbtx
Founded 2023 · 20 employees on LinkedIn · 5 known investors
Find your way into Reverbtx
Sign up to see every warm intro you have to Reverbtx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Reverbtx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Reverb Therapeutics develops immunotherapies built on its Amplify•R platform, which modulates the body's natural immune system using targeted molecules such as IL-15-directed compounds. Its pipeline addresses cancer, autoimmune disease, and cell therapy support, with lead candidate AMP01 advancing toward clinical trials.
Investors · 5
How we know: Amplitude Venture Capital's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Finchley Healthcare Ventures's portfolio page · Not right? Tell us
How we know: InBC Investment Corp.'s portfolio page · Not right? Tell us
How we know: Thin Air Labs's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Reverbtx do?
- Reverb Therapeutics develops immunotherapies built on its Amplify•R platform, which modulates the body's natural immune system using targeted molecules such as IL-15-directed compounds. Its pipeline addresses cancer, autoimmune disease, and cell therapy support, with lead candidate AMP01 advancing toward clinical trials.
- Who are Reverbtx's investors?
- Reverbtx's investors include Amplitude Venture Capital, Finchley Healthcare Ventures, InBC Investment Corp., Thin Air Labs, KdT Ventures.